Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645287 | 0.69 | CYP3A4 (0.42) | ALDH1A1KMT2ARAB9AMEN1MAPT | |
| Acridine SCHEMBL27545385 | 0.69 | RAB9A (0.63) | ALDH1A1KMT2ARAB9AMEN1MAPT | |
| SCHEMBL28818163 | 0.69 | RAB9A (0.54) | ALDH1A1KMT2ARAB9AMEN1MAPT | |
| SCHEMBL269884 | 0.68 | ALDH1A1 (0.46) | ALDH1A1KMT2ARAB9AMEN1MAPT | |
| SCHEMBL7060124 | 0.68 | ALDH1A1 (0.46) | ALDH1A1KMT2ARAB9AMAPTGLA | |
| Acridine SCHEMBL2772852 | 0.68 | ALDH1A1 (0.65) | ALDH1A1KMT2ARAB9AMEN1MAPT | |
| SCHEMBL584784 | 0.68 | ALDH1A1 (0.46) | ALDH1A1KMT2ARAB9AMAPTGLA | |
| SCHEMBL521935 | 0.68 | NQO2 (0.46) | ALDH1A1KMT2ARAB9AMEN1MAPT | |
| SCHEMBL558480 | 0.68 | ALDH1A1 (0.46) | ALDH1A1KMT2ARAB9AMAPTGLA | |
| SCHEMBL641339 | 0.68 | ALDH1A1 (0.47) | ALDH1A1KMT2ARAB9AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5403932-A | Phosphoramidates useful as antitumor agents | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-04-04 | — | — | US | claimed |
| US-5270308-A | Hypotensives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-12-14 | — | — | US | claimed |
| EP-0418292-A4 | PHOSPHORAMIDES USEFUL AS ANTITUMOR AGENTS | — | 1991-09-25 | — | — | EP | claimed |
| EP-0418292-A1 | PHOSPHORAMIDES USEFUL AS ANTITUMOR AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-03-27 | — | — | EP | claimed |
| WO-1989011484-A1 | PHOSPHORAMIDES USEFUL AS ANTITUMOR AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1989-11-30 | — | — | WO | claimed |
| US-4457866-A | MEDICAL DIAGNOSIS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1984-07-03 | — | — | US | claimed |
| EP-0025190-B1 | CHROMOGENIC COMPOUNDS AND THEIR USE AS ENZYMATIC SUBSTRATES | BEHRINGWERKE Aktiengesellschaft (DE) | 1984-06-13 | — | — | EP | claimed |
| US-4247454-A | Novel chromogenic thrombin substrates | AB KABI (SE) | 1981-01-27 | — | — | US | claimed |
| US-4214049-A | SPECTROPHOTOMETRIC ANALYSIS OF HYDROLYSIS PRODUCTS | AB KABI (SE) | 1980-07-22 | — | — | US | claimed |
| US-4169015-A | PHENYLALANINE OR TYROSINE-AZEIDINE CARBOXYLIC ACID, PROLINE OR PIPECOLINIC ACID-ARGININE-CHROMOPHORE, SPECTROPHOTOMETRIC ANALYSIS OF ENZYMATIC HYDROLYSIS | AB KABI (SE) | 1979-09-25 | — | — | US | claimed |
| US-4162941-A | CONTACTING WITH A PEPTIDE SUBSTRATE AND MEASURING THE ENZYMATIC HYDROLYSIS | AB KABI (SE) | 1979-07-31 | — | — | US | claimed |
| US-4137225-A | SPECIFIC FOR SERINE PROTEASE, ENANTIOMORPHS | AB KABI (SE) | 1979-01-30 | — | — | US | claimed |
| US-4072576-A | Method for studying enzymatic and other biochemical reactions | AB KABI (SW) | 1978-02-07 | — | — | US | claimed |
| US-4028318-A | FOR SERINE PROTEASES | A B KABI (SW) | 1977-06-07 | — | — | US | claimed |
| EP-1984366-B1 | 3, 9-DIAZABICYCLO Ý3.3. 1¨NONANE DERIVATIVES AND THEIR USE AS MONOAMINE?NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-12-15 | — | — | EP | disclosed |
| US-7687517-B2 | 3,9-Diazabicyclo [3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-03-30 | — | — | US | disclosed |
| US-20080306078-A1 | 3,9-Diazabicyclo [3.3.1] Nonane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | DANPET AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-4028318-A | FOR SERINE PROTEASES | A B KABI (SW) | 1977-06-07 | — | — | US | disclosed |
| US-4028318-A | FOR SERINE PROTEASES | A B KABI (SW) | 1977-06-07 | — | — | US | disclosed |
| US-3886136-A | New substrates for diagnostic use, with high susceptibility to trypsin and other proteolytic enzymes of the type peptide peptidohydrolases | BOFORS AB | 1975-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306078-A1 | 3,9-Diazabicyclo [3.3.1] Nonane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC18A3 | ALDH1A1 608/4885KMT2A 2224/4885RAB9A 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.